Identification

Name
Enalapril
Accession Number
DB00584  (APRD00510)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Enalapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalaprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure.

Structure
Thumb
Synonyms
  • (S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
  • (S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
  • 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
  • Analapril
  • Enalapril
  • Enalaprila
  • Enalaprilum
External IDs
C09AA02 / L 154739-01 D / MK 421
Product Ingredients
IngredientUNIICASInChI Key
Enalapril maleate9O25354EPJ76095-16-4OYFJQPXVCSSHAI-QFPUQLAESA-N
Enalapril sodium94A7UFL2SI149404-21-7FTTHROYWFRGKST-BDURURIASA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act EnalaprilTablet4 mgOralTeva2007-10-17Not applicableCanada
Act EnalaprilTablet16 mgOralTeva2007-10-17Not applicableCanada
Act EnalaprilTablet2 mgOralTeva2007-10-17Not applicableCanada
Act EnalaprilTablet8 mgOralTeva2007-10-17Not applicableCanada
Ava-enalaprilTablet20.0 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-enalaprilTablet2.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-enalaprilTablet10.0 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-enalaprilTablet5.0 mgOralAvanstra Inc2011-10-112014-08-21Canada
Dom-enalaprilTablet8 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-enalaprilTablet4 mgOralDominion PharmacalNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-enalapril Tab 10mgTablet10 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-enalapril Tab 2.5mgTablet2.5 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-enalapril Tab 20mgTablet20 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-enalapril Tab 5mgTablet5 mgOralApotex Corporation1993-12-31Not applicableCanada
Enalapril MaleateTablet10 mg/1OralGolden State Medical Supply2013-11-04Not applicableUs
Enalapril MaleateTablet10 mg/1OralGolden State Medical Supply2011-05-122015-11-30Us
Enalapril MaleateTablet20 mg/1OralRanbaxy Inc.2016-09-17Not applicableUs
Enalapril MaleateTablet10 mg/1OralWockhardt2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralMylan Institutional2000-11-15Not applicableUs
Enalapril MaleateTablet10 mg/1OralRemedy Repack2013-06-142016-10-25Us
International/Other Brands
Acetec (Alphapharm) / Acetensil (Grünenthal) / Alapren (Ranbaxy) / Amotac (Mass Pharma) / Amprace (Merck Sharp & Dohme) / Dilvas (Cipla) / Diotensil (Mintlab) / Drepatil (Fada) / Enace (Abbott) / EnaHexal (Sandoz) / Enal (East West) / Enalapoten (Del Bel) / Enpril (Wockhardt) / Feliberal (Silanes) / Gadopril (Gador (Argentina)) / Glioten (Bago) / Kinfil (Nova Argentia (Argentina)) / Vasotec IV (Sandoz (Canada))
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-enalapril Maleate/hctzEnalapril maleate (5.0 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2011-02-24Not applicableCanada
Apo-enalapril Maleate/hctzEnalapril maleate (10 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2011-02-24Not applicableCanada
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (10 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralTeva2001-09-192016-04-30Us
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (10 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralApotex Corporation2007-06-192017-02-23Us60505 0209 01 nlmimage10 5a462d51
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (5 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralGw Pharmaceuticals Ltd.2016-03-31Not applicableUs
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (10 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralTaro Pharmaceuticals U.S.A., Inc.2001-09-18Not applicableUs
Enalapril maleate and hydrochlorothiazideEnalapril maleate (5 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralDr Reddy's Laboratories2001-10-15Not applicableUs
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (10 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2009-07-23Not applicableUs
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (5 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralMylan Pharmaceuticals2001-09-19Not applicableUs00378 0712 01 nlmimage10 af4057d2
Enalapril Maleate and HydrochlorothiazideEnalapril maleate (5 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralRemedy Repack2013-11-122016-12-24Us60505 0208 01 nlmimage10 113a0880
Categories
UNII
69PN84IO1A
CAS number
75847-73-3
Weight
Average: 376.4467
Monoisotopic: 376.199822016
Chemical Formula
C20H28N2O5
InChI Key
GBXSMTUPTTWBMN-XIRDDKMYSA-N
InChI
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]@H](C)C(=O)N1CCC[[email protected]]1C(O)=O

Pharmacology

Indication

For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.

Structured Indications
Pharmacodynamics

Enalapril is a prodrug that is rapidly metabolized by liver esterases to enalaprilat following oral administration. Enalapril itself has little pharmacologic activity. Enalaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of enalaprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Enalaprilat, the principle active metabolite of enalapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Enalapril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Enalaprilat's affinity for ACE is approximately 200,000 times greater than that of ATI and 300-1000 times greater than that enalapril.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

55-75%, absorption is unaffected by food; enalaprilat (clinically administered IV) is poorly absorbed, 3-12%, due to its high polarity.

Volume of distribution
Not Available
Protein binding

50-60% of enalaprilat is bound to plasma proteins

Metabolism

~ 60% of absorbed dose is extensively hydrolyzed to enalaprilat, primarily by liver esterases

Route of elimination

Excretion of enalapril is primarily renal.

Half life

< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.

Clearance
Not Available
Toxicity

Overdosage may result in marked hypotension and stupor. Most common adverse effects include hypotension, headache, dizziness and fatigue.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Enalapril Action PathwayDrug action
Enalapril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Enalapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Enalapril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Enalapril is combined with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Enalapril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Enalapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Enalapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Enalapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Enalapril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Enalapril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Enalapril.Approved, Illicit, Investigational
AlprenololEnalapril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanEnalapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalapril.Experimental, Investigational
AmifostineEnalapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Enalapril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Enalapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Enalapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Enalapril.Approved
AmiodaroneThe metabolism of Enalapril can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Enalapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Enalapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Enalapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Enalapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Enalapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Enalapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Enalapril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Enalapril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Enalapril is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Enalapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Enalapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Enalapril is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Enalapril can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Enalapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Enalapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalapril.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalapril.Approved, Investigational
AtazanavirThe metabolism of Enalapril can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Enalapril.Approved
AtomoxetineThe metabolism of Enalapril can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Enalapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Enalapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Azapropazone.Withdrawn
AzathioprineEnalapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Enalapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Enalapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Enalapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Enalapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Enalapril.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Enalapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Enalapril is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Enalapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Enalapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Enalapril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Benzydamine.Approved
BepridilEnalapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Enalapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Enalapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Enalapril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Enalapril.Experimental
BimatoprostEnalapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Enalapril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Enalapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Enalapril can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Enalapril can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Enalapril.Approved
BQ-123Enalapril may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enalapril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Enalapril is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Enalapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Enalapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Enalapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Enalapril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Enalapril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalapril.Approved, Investigational
BupranololEnalapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Enalapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Enalapril.Experimental
CafedrineEnalapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Enalapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Enalapril.Approved
CandoxatrilEnalapril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Captopril.Approved
CarbamazepineThe metabolism of Enalapril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Enalapril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Enalapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Enalapril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Enalapril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Enalapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Celecoxib.Approved, Investigational
CeliprololEnalapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Enalapril can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Enalapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Enalapril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Enalapril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Enalapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Enalapril is combined with Choline magnesium trisalicylate.Approved
CicletanineEnalapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalapril.Approved, Investigational
CiprofloxacinEnalapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Enalapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalapril.Approved
ClemastineThe metabolism of Enalapril can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Enalapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Enalapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Enalapril is combined with Clonixin.Approved
CloranololEnalapril may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Enalapril can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Enalapril.Approved
CobicistatThe metabolism of Enalapril can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Enalapril.Approved
ConivaptanThe serum concentration of Enalapril can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Enalapril.Approved
CrizotinibThe metabolism of Enalapril can be decreased when combined with Crizotinib.Approved
CryptenamineEnalapril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Enalapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalapril.Approved
CyclopenthiazideEnalapril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Enalapril.Approved, Investigational, Vet Approved
CyclothiazideEnalapril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Enalapril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enalapril.Approved
DabrafenibThe serum concentration of Enalapril can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Enalapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Enalapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Enalapril.Investigational
DarunavirThe metabolism of Enalapril can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Enalapril can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Enalapril.Approved, Investigational
DeferasiroxThe serum concentration of Enalapril can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilEnalapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Enalapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Enalapril.Investigational
DeserpidineEnalapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Enalapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Enalapril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Enalapril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Enalapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Enalapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Enalapril.Approved, Investigational
diethylnorspermineEnalapril may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Enalapril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Enalapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Enalapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Enalapril.Investigational
DihydroergotamineThe metabolism of Enalapril can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Enalapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Enalapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Dipyridamole.Approved
DorzolamideEnalapril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Enalapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Enalapril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Enalapril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Enalapril.Approved, Investigational
DoxycyclineThe metabolism of Enalapril can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Enalapril can be decreased when combined with Dronedarone.Approved
DrospirenoneEnalapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Droxicam.Approved
DuloxetineEnalapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Enalapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Enalapril.Approved
E-6201The risk or severity of adverse effects can be increased when Enalapril is combined with E-6201.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Enalapril.Approved
EfonidipineEnalapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Enalapril is combined with Empagliflozin.Approved
EnalaprilatEnalapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Enalapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Enalapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Enalapril.Approved
EnzalutamideThe serum concentration of Enalapril can be decreased when it is combined with Enzalutamide.Approved
EpanololEnalapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Enalapril.Approved
EpoprostenolEnalapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Enalapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Enalapril.Approved
ErythromycinThe metabolism of Enalapril can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Enalapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Enalapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Enalapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Enalapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Enalapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Enalapril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Enalapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Enalapril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Enalapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Enalapril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Enalapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Enalapril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Enalapril is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Enalapril is combined with Fenbufen.Approved
FenoldopamEnalapril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Enalapril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Feprazone.Experimental
Ferulic acidEnalapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Enalapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Enalapril is combined with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Enalapril can be decreased when combined with Fluconazole.Approved
FlunixinThe risk or severity of adverse effects can be increased when Enalapril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Flurbiprofen.Approved, Investigational
FluvoxamineThe metabolism of Enalapril can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalapril.Experimental
FosamprenavirThe metabolism of Enalapril can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Enalapril can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Enalapril.Approved
FosphenytoinThe metabolism of Enalapril can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Enalapril.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Enalapril is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Enalapril can be increased when it is combined with Fusidic Acid.Approved
GarlicThe serum concentration of Enalapril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Enalapril.Experimental
GuanabenzEnalapril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Enalapril.Approved
GuanazodineEnalapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineEnalapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Enalapril is combined with Guanfacine.Approved, Investigational
GuanoclorEnalapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzEnalapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanEnalapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Enalapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Enalapril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Enalapril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational
HexamethoniumEnalapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Enalapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Enalapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Enalapril.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideEnalapril may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Enalapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Enalapril.Approved
IloprostIloprost may increase the hypotensive activities of Enalapril.Approved, Investigational
ImatinibThe metabolism of Enalapril can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Enalapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Enalapril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Enalapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Indapamide.Approved
IndenololEnalapril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Enalapril can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Enalapril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Enalapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Enalapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Enalapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Enalapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Enalapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron Dextran.Approved, Vet Approved
IsavuconazoniumThe metabolism of Enalapril can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Enalapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Enalapril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Enalapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Enalapril.Approved
ItraconazoleThe metabolism of Enalapril can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Enalapril can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Enalapril.Investigational
KetoconazoleThe metabolism of Enalapril can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Enalapril is combined with Labetalol.Approved
LacidipineEnalapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Enalapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostEnalapril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Enalapril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Enalapril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Enalapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Enalapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Enalapril.Approved, Investigational
LevodopaEnalapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Enalapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Enalapril.Approved
LinsidomineEnalapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Enalapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Enalapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Enalapril.Experimental
LofexidineEnalapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Enalapril is combined with Lonazolac.Experimental
LopinavirThe metabolism of Enalapril can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Enalapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Enalapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Enalapril can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Enalapril can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Lumiracoxib.Approved, Investigational
MacitentanEnalapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Enalapril is combined with Magnesium salicylate.Approved
ManidipineEnalapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Enalapril is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Enalapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Enalapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Enalapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Enalapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Enalapril.Approved
MethoserpidineEnalapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Enalapril.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Enalapril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Enalapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Enalapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Enalapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Enalapril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Enalapril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Enalapril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Enalapril.Approved, Investigational
MetyrosineEnalapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilEnalapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Enalapril.Approved, Illicit
MifepristoneThe serum concentration of Enalapril can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Enalapril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Enalapril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Enalapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Enalapril.Approved
MitotaneThe serum concentration of Enalapril can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Enalapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Enalapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Enalapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Enalapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Enalapril.Approved, Investigational
MuzolimineEnalapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Enalapril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Enalapril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Enalapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Enalapril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Enalapril is combined with Naftifine.Approved
NaftopidilEnalapril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Enalapril.Approved
NaproxenThe risk or severity of adverse effects can be increased when Enalapril is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Enalapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Enalapril.Approved, Withdrawn
NelfinavirThe metabolism of Enalapril can be decreased when combined with Nelfinavir.Approved
NepafenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Enalapril is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Enalapril can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Enalapril can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Enalapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Enalapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Enalapril is combined with Niflumic Acid.Approved
NiguldipineEnalapril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Enalapril can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineEnalapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Enalapril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Enalapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Enalapril.Approved
NitrendipineEnalapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Enalapril.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Enalapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Enalapril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Enalapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Enalapril.Approved
ObinutuzumabEnalapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Enalapril.Withdrawn
OlaparibThe metabolism of Enalapril can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Enalapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Olsalazine.Approved
OmapatrilatEnalapril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Enalapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Enalapril is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Enalapril can be increased when it is combined with Osimertinib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxaprozin.Approved
OxprenololEnalapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enalapril.Approved, Vet Approved
PalbociclibThe serum concentration of Enalapril can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Enalapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Enalapril is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Enalapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Enalapril is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Enalapril can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumEnalapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Enalapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Enalapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Enalapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Enalapril.Withdrawn
PhenobarbitalThe metabolism of Enalapril can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineEnalapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Enalapril.Withdrawn
PhentolamineEnalapril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Enalapril can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Enalapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Enalapril.Approved
PinacidilPinacidil may increase the hypotensive activities of Enalapril.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Enalapril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Enalapril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Enalapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Enalapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Enalapril.Withdrawn
Platelet Activating FactorEnalapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideEnalapril may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Enalapril can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Enalapril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Enalapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Enalapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidoneThe metabolism of Enalapril can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Enalapril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Enalapril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Enalapril is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Enalapril.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Enalapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Enalapril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Enalapril.Approved
PTC299The risk or severity of adverse effects can be increased when Enalapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Enalapril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Enalapril.Approved
QuinineQuinine may increase the hypotensive activities of Enalapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Enalapril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Enalapril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Enalapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Enalapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Enalapril.Approved
RescinnamineEnalapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Enalapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Enalapril is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational
RifabutinThe metabolism of Enalapril can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Enalapril can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Enalapril can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Enalapril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Enalapril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Enalapril.Approved
RisperidoneEnalapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEnalapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Enalapril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Enalapril.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Enalapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Enalapril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Enalapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Enalapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalapril.Experimental
SaquinavirThe metabolism of Enalapril can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Enalapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Enalapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Enalapril.Approved, Investigational, Vet Approved
SelexipagEnalapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Enalapril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Enalapril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Enalapril is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Enalapril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Enalapril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Enalapril.Approved
SiltuximabThe serum concentration of Enalapril can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Enalapril can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Enalapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Enalapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalapril.Approved, Investigational
SitaxentanEnalapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Enalapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Enalapril.Approved
Sodium phosphateEnalapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Enalapril.Approved
SpiraprilEnalapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Enalapril.Approved
SRT501The risk or severity of adverse effects can be increased when Enalapril is combined with SRT501.Investigational
St. John's WortThe serum concentration of Enalapril can be decreased when it is combined with St. John&#39;s Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Enalapril can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Enalapril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Enalapril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Enalapril can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enalapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Enalapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Enalapril.Approved, Investigational
TalinololEnalapril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Enalapril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Enalapril.Approved
TelaprevirThe metabolism of Enalapril can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Enalapril can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalapril.Approved, Investigational
TemocaprilEnalapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Enalapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Enalapril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Enalapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Enalapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Enalapril is combined with Teriflunomide.Approved
TerlipressinEnalapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineEnalapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Enalapril.Approved, Investigational, Withdrawn
TheodrenalineEnalapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Enalapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Enalapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Enalapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Enalapril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Enalapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Tiaprofenic acid.Approved
TiboloneEnalapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Enalapril can be decreased when combined with Ticlopidine.Approved
TicrynafenEnalapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Enalapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Enalapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Enalapril.Approved
TipranavirThe serum concentration of Enalapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Enalapril.Approved
TocilizumabThe serum concentration of Enalapril can be decreased when it is combined with Tocilizumab.Approved
TolazolineEnalapril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Enalapril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolmetin.Approved
TolonidineEnalapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Enalapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Enalapril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Enalapril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Enalapril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Enalapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Enalapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Enalapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Enalapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Enalapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Enalapril.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Enalapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Enalapril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Enalapril is combined with Tribenoside.Experimental
TrichlormethiazideEnalapril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Enalapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Enalapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Enalapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Enalapril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Enalapril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Enalapril.Approved, Investigational
UnoprostoneEnalapril may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Enalapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Enalapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Enalapril.Approved
VenlafaxineThe metabolism of Enalapril can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Enalapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalapril.Approved, Investigational
VincamineEnalapril may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Enalapril.Approved, Investigational
VinpocetineEnalapril may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Enalapril can be decreased when combined with Voriconazole.Approved, Investigational
XipamideEnalapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineEnalapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Enalapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Enalapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Enalapril can be decreased when combined with Ziprasidone.Approved
ZofenoprilEnalapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Enalapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Enalapril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of enalapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of enalapril.
  • Take without regard to meals.

References

Synthesis Reference

K. S. Keshava Murthy, Andrew Burchat, Gamini Weeratunga, "Sodium enalapril complex and the use thereof to make sodium enalapril." U.S. Patent US5637730, issued February, 1983.

US5637730
General References
  1. Florey, Klaus;Al-Badr, Abdullah A.;Brenner, Gerald S. (1987). Analytical Profiles of Drug Substances (16th ed.). Elsevier Science & Technology Books. [ISBN:978-0-12-260816-2]
External Links
Human Metabolome Database
HMDB14722
KEGG Compound
C06977
PubChem Compound
5388962
PubChem Substance
46507920
ChemSpider
4534998
BindingDB
50017129
ChEBI
4784
ChEMBL
CHEMBL578
Therapeutic Targets Database
DAP001374
PharmGKB
PA449456
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Enalapril
ATC Codes
C09BB06 — Enalapril and nitrendipineC09BB02 — Enalapril and lercanidipineC09AA02 — EnalaprilC09BA02 — Enalapril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (939 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceEsophagus, Barrett1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Enalapril1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1RecruitingTreatmentHypertension, Resistant to Conventional Therapy1
1Unknown StatusNot AvailableDiabetic Macular Ischemia1
1Unknown StatusTreatmentHeart Failure, Unspecified1
1, 2Unknown StatusTreatmentRenal Insufficiency,Chronic1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) / Vascular Diseases1
2CompletedTreatmentHigh Blood Pressure (Hypertension)1
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentIntracerebral Hemorrhage1
2CompletedTreatmentPseudohypoaldosteronism1
2RecruitingPreventionLung Cancers / Radiation Pneumonitis1
2RecruitingTreatmentIntracerebral Hemorrhage1
2TerminatedTreatmentMetastatic Malignant Melanoma / Unresectable Malignant Melanoma1
2, 3CompletedPreventionHypertension Secondary to Kidney Transplant1
2, 3RecruitingTreatmentAngioplasty, Balloon, Coronary / Contrast Media / Coronary Heart Disease (CHD) / High Blood Pressure (Hypertension) / Homocysteine / Renal Dysfunction1
2, 3RecruitingTreatmentPediatric Heart Failure1
3Active Not RecruitingTreatmentCancers1
3Active Not RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
3CompletedPreventionAutologous Hematopoietic Stem Cell Transplantation / Leukemia Acute Myeloid Leukemia (AML) / Lymphoid Neoplasms / Malignant Lymphomas / Multiple Myeloma (MM) / Precursor-cell Lymphoblastic Leukemia-Lymphoma1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Heart Failure, Unspecified / High Blood Pressure (Hypertension) / Myocardial Ischemia1
3CompletedPreventionHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedSupportive CareCardiac Toxicity / Unspecified Childhood Solid Tumor, Protocol Specific1
3CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Heart Failure, Unspecified / Myocardial Diseases1
3CompletedTreatmentChronic Heart Failure (CHF)1
3CompletedTreatmentCongestive Cardiomyopathy / High Blood Pressure (Hypertension)1
3CompletedTreatmentCongestive Heart Failure (CHF) / Heart Defects,Congenital1
3CompletedTreatmentCongestive Heart Failure (CHF) / Heart Failure With Preserved Ejection Fraction (HFpEF)1
3CompletedTreatmentHigh Blood Pressure (Hypertension)5
3CompletedTreatmentMuscular Dystrophy / Myocardial Fibrosis1
3CompletedTreatmentProteinuria1
3RecruitingPreventionCancer, Breast1
3RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
3RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
3TerminatedTreatmentCongestive Heart Failure (CHF) / Heart Defects,Congenital / Heart Septal Defects, Ventricular1
3TerminatedTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4CompletedBasic ScienceCarboxylesterase 1 (CES1) Genotype / CES1 Activity1
4CompletedBasic ScienceHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedPreventionCardiotoxicity / Chemotherapeutic Toxicity / Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase1
4CompletedPreventionHypertension,Essential1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHigh Blood Pressure (Hypertension)4
4CompletedTreatmentMacroalbuminuric Diabetic Nephropathy1
4Not Yet RecruitingTreatmentHypertension,Essential1
4RecruitingOtherHeart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingScreeningHealthy Volunteers1
4RecruitingSupportive CareAcute Heart Failure (AHF)1
4RecruitingTreatmentBody Composition / Exercise Tolerance / Heart Failure, Unspecified / Strength, Muscle / Vasodilation1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentRecurrent IgA Nephropathy1
4TerminatedPreventionDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4Unknown StatusPreventionAtherosclerosis / Cardiovascular Disease (CVD)1
4Unknown StatusPreventionContinuous ambulatory peritoneal dialysis therapy1
4Unknown StatusTreatmentCardiovascular Disease (CVD) / Kidney Failure,Chronic1
4Unknown StatusTreatmentHeart Failure, Unspecified1
4WithdrawnPreventionHigh Blood Pressure (Hypertension) / Hyperhomocysteinaemia1
Not AvailableCompletedNot AvailableFabry's Disease / Proteinuria1
Not AvailableCompletedSupportive CareOrthognathic Surgery1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Microalbuminuria1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Proteinuria1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentIgA Glomerulonephritis1
Not AvailableCompletedTreatmentRenal Transplant Patients1
Not AvailableTerminatedTreatmentSickle Cell Disorders1
Not AvailableUnknown StatusPreventionMicroalbuminuria / Sickle Cell Nephropathy1
Not AvailableUnknown StatusPreventionPre-Diabetic / Pre-Hypertension1
Not AvailableUnknown StatusTreatmentCancer, Breast1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Apothecon inc div bristol myers squibb
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Krka dd novo mesto
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wockhardt americas inc
  • Biovail laboratories international srl
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral2.5 mg
TabletOral20 mg
TabletOral5 mg
TabletOral10.0 mg
TabletOral20.0 mg
TabletOral5.0 mg
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Tablet, solubleOral10 mg/1
Tablet, solubleOral2.5 mg/1
Tablet, solubleOral20 mg/1
Tablet, solubleOral5 mg/1
TabletOral
Kit
SolutionOral1 mg/mL
TabletOral32 mg
TabletOral2 mg
TabletOral4.0 mg
TabletOral8.0 mg
TabletOral16 mg
TabletOral2.0 mg
TabletOral4 mg
TabletOral8 mg
Prices
Unit descriptionCostUnit
Enalapril maleate powder9.18USD g
Enalaprilat 1.25 mg/ml vial3.6USD ml
Vasotec 20 mg tablet3.36USD tablet
Vaseretic 10-25 mg tablet3.15USD tablet
Vasotec 10 mg tablet2.63USD tablet
Vasotec 5 mg tablet2.08USD tablet
Vasotec 2.5 mg tablet1.65USD tablet
Enalapril maleate 20 mg tablet1.56USD tablet
Vaseretic 5-12.5 mg tablet1.49USD tablet
Vasotec 20 mg Tablet1.34USD tablet
Vasotec 10 mg Tablet1.11USD tablet
Enalapril maleate 10 mg tablet1.09USD tablet
Enalapril maleate 5 mg tablet1.03USD tablet
Vasotec 5 mg Tablet0.92USD tablet
Enalapril maleate 2.5 mg tablet0.82USD tablet
Vasotec 2.5 mg Tablet0.78USD tablet
Apo-Enalapril 20 mg Tablet0.75USD tablet
Co Enalapril 20 mg Tablet0.75USD tablet
Mylan-Enalapril 20 mg Tablet0.75USD tablet
Novo-Enalapril 20 mg Tablet0.75USD tablet
Pms-Enalapril 20 mg Tablet0.75USD tablet
Ratio-Enalapril 20 mg Tablet0.75USD tablet
Sandoz Enalapril 20 mg Tablet0.75USD tablet
Taro-Enalapril 20 mg Tablet0.75USD tablet
Apo-Enalapril 10 mg Tablet0.62USD tablet
Co Enalapril 10 mg Tablet0.62USD tablet
Mylan-Enalapril 10 mg Tablet0.62USD tablet
Novo-Enalapril 10 mg Tablet0.62USD tablet
Pms-Enalapril 10 mg Tablet0.62USD tablet
Ratio-Enalapril 10 mg Tablet0.62USD tablet
Sandoz Enalapril 10 mg Tablet0.62USD tablet
Taro-Enalapril 10 mg Tablet0.62USD tablet
Apo-Enalapril 5 mg Tablet0.52USD tablet
Co Enalapril 5 mg Tablet0.52USD tablet
Mylan-Enalapril 5 mg Tablet0.52USD tablet
Novo-Enalapril 5 mg Tablet0.52USD tablet
Pms-Enalapril 5 mg Tablet0.52USD tablet
Ratio-Enalapril 5 mg Tablet0.52USD tablet
Sandoz Enalapril 5 mg Tablet0.52USD tablet
Taro-Enalapril 5 mg Tablet0.52USD tablet
Apo-Enalapril 2.5 mg Tablet0.44USD tablet
Co Enalapril 2.5 mg Tablet0.44USD tablet
Mylan-Enalapril 2.5 mg Tablet0.44USD tablet
Novo-Enalapril 2.5 mg Tablet0.44USD tablet
Pms-Enalapril 2.5 mg Tablet0.44USD tablet
Ratio-Enalapril 2.5 mg Tablet0.44USD tablet
Sandoz Enalapril 2.5 mg Tablet0.44USD tablet
Taro-Enalapril 2.5 mg Tablet0.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8778366No2012-11-062032-11-06Us
US8568747No2012-11-062032-11-06Us
US9669008No2016-03-252036-03-25Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)143-144.5 °CNot Available
water solubility1.64E+004 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.07HANSCH,C ET AL. (1995)
Caco2 permeability-5.64ADME Research, USCD
pKa2.97 (the carboxyl group) and 5.35 (the amine group) at 25°CNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.213 mg/mLALOGPS
logP0.19ALOGPS
logP0.59ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.67ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity99.57 m3·mol-1ChemAxon
Polarizability40.41 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7428
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8956
P-glycoprotein substrateSubstrate0.7691
P-glycoprotein inhibitor INon-inhibitor0.6681
P-glycoprotein inhibitor IINon-inhibitor0.5136
Renal organic cation transporterNon-inhibitor0.8442
CYP450 2C9 substrateNon-substrate0.8632
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5696
CYP450 1A2 substrateNon-inhibitor0.9125
CYP450 2C9 inhibitorNon-inhibitor0.9154
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6825
Ames testNon AMES toxic0.9383
CarcinogenicityNon-carcinogens0.9216
BiodegradationNot ready biodegradable0.8686
Rat acute toxicity1.8269 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9719
hERG inhibition (predictor II)Non-inhibitor0.7456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0809000000-0e192d1573028e60641c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-003r-1859000000-8b202071e8860792a59f

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Proline and derivatives / Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Fatty acid esters / Benzene and substituted derivatives / Dicarboxylic acids and derivatives
show 10 more
Substituents
Alpha-dipeptide / N-acyl-alpha amino acid or derivatives / N-acyl-alpha-amino acid / N-acyl-l-alpha-amino acid / Proline or derivatives / Alpha-amino acid ester / Alpha-amino acid amide / Alpha-amino acid or derivatives / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine carboxylic acid
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dicarboxylic acid monoester, dipeptide (CHEBI:4784)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Liu YH, Liu LY, Wu JX, Chen SX, Sun YX: Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice. J Cardiovasc Pharmacol. 2006 Jan;47(1):82-8. [PubMed:16424790]
  4. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR: Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. [PubMed:15236580]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL: 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998 Aug;15(8):1154-9. [PubMed:9706043]
  2. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50. [PubMed:10052994]
  3. Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81. [PubMed:9733984]
  4. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749]
  2. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Abu-Zahra TN, Wolkoff AW, Kim RB, Pang KS: Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6. [PubMed:10859154]
  2. Pang KS, Wang PJ, Chung AY, Wolkoff AW: The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6. [PubMed:9794920]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18